Showing results (2631-2640 of 2,729) with videos related to

Sort By:
Pageof 273
Nature Communications|October 4, 2018
Publisher Correction: Critical Southern Ocean climate model biases traced to atmospheric model cloud errorsPatrick Hyder, John M Edwards, Richard P Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
JACC. Clinical Electrophysiology|May 15, 2026
Epinephrine Challenge: Long-Term Evaluation of Test Performance for the Evaluation of Unexplained Cardiac Arrest and Familial Sudden DeathBenjamin M Moore, Christian Steinberg, Rafik Tadros, et al.
Journal of Medicinal Chemistry|July 10, 2015
Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain InhibitorsEmmanuel H Demont, Chun-wa Chung, Rebecca C Furze, et al.
JACC. Clinical Electrophysiology|May 16, 2018
Bundle Branch Re-Entrant Ventricular Tachycardia: Novel Genetic Mechanisms in a Life-Threatening ArrhythmiaJason D Roberts, Michael H Gollob, Charlie Young, et al.
Cell Chemical Biology|February 4, 2018
Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative BacteriaTony Velkov, Alejandra Gallardo-Godoy, James D Swarbrick, et al.
JACC. Basic to Translational Science|April 12, 2026
Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 DiabetesOliver I Brown, Katherine I Bridge, Alexander-Francisco Bruns, et al.
JACC. Clinical Electrophysiology|April 20, 2019
Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada SyndromeChristopher C Cheung, Greg Mellor, Marc W Deyell, et al.
Circulation|December 4, 2025
Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada SyndromeBenjamin M Moore, Douglas Chan, Brianna Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Pageof 273